Company intelligence / Profile preview

Ceretype Neuromedicine

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Ceretype Neuromedicine has developed and launched a scalable, cloud-based platform that translates fMRI-based brain activity mapping into actionable, reproducible biomarkers for neuropsychiatric and neurological disease research, development, and clinical support. Its Brain Insight Report and platform are being used for cohorting, treatment effect measurement, and supporting drug/device trials; clinical validation is ongoing with initial applications in psychiatric and neurodegenerative diseases.[1][4]

Therapeutic areas: NeurologyPsychiatry
Industry: Medical Imaging

Partnerships

One Mind Accelerator (startup support/collaboration)[4]Calyx Medical Imaging (technology integration for neuropsychiatric treatment development)[3]

Beyond the preview

Go deeper on Ceretype Neuromedicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceretype Neuromedicine.

Explore the full profile